Skip to content

The efficacy and safety of perospirone hydrochloride tablets in the treatment of schizophrenia: a multicenter, one-armed, prospective real-world study

The efficacy and safety of perospirone hydrochloride tablets in the treatment of schizophrenia: a multicenter, one-armed, prospective real-world study

Status
Recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200063355
Enrollment
Unknown
Registered
2022-09-05
Start date
2022-09-12
Completion date
Unknown
Last updated
2023-04-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia

Interventions

one:Oral Perospirone Hydrochloride Tablets

Sponsors

Peking University Sixth Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1.Male or female patients >= 18 years old and <= 65 years old 2.Diagnosis of schizophrenia by psychiatrist(according to ICD-10); 3.Plan to use perospirone hydrochloride tablets,including: (1) First episode patients; (2) Original treatment was ineffective; (3) Adverse reactions or intolerance; 4.The participants or their guardians signed the informed consent before entering the trial.

Exclusion criteria

Exclusion criteria: 1. Previous history of serious suicide acts or attempts; 2. Poor medication or follow-up compliance; 3. Taking other antipsychotics to treat schizophrenia,short-term (<= 2 weeks)drug combinations were allowed; 4. Pregnant or breast-feeding women or those planning to become pregnant; 5. Other circumstances that the investigator considers inappropriate to participate in this clinical study.

Design outcomes

Primary

MeasureTime frame
The Schizophrenia Quality of Life Scale;The Brief Psychiatric Rating Scale;

Secondary

MeasureTime frame
Personal and Social Performance Scale; Brief Assessment of Cognition in Schizophrenia;Psychotropic-Related Sexual Dysfunction Questionnaire;Incidence of abnormal body weight;Waist circumference;Incidence of abnormal blood sugar;Incidence of dyslipidemia;Incidence of abnormal serum prolactin;

Countries

China

Contacts

Public ContactChuan Shi

Peking University Sixth Hospital

shichuan@bjmu.edu.cn+86 10 82806157

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026